Skip to main content
Erschienen in: Supportive Care in Cancer 7/2013

01.07.2013 | Original Article

Medication use in breast cancer survivors compared to midlife women

verfasst von: Julie L. Otte, Todd C. Skaar, Jingwei Wu, Menggang Yu, Kristin Ryker, Debra S. Burns, Janet S. Carpenter

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many breast cancer survivors (BCS) take multiple medications for health problems associated with the treated cancer and other noncancer comorbidities. However, there is no published, large-scale descriptive evaluation of medication use in BCS compared to midlife women. The purpose of this study was (1) to compare the number and types of prescription medications and over-the-counter medications between BCS and midlife women without cancer and (2) to assess possible drug–drug interactions by evaluating the cytochrome P450 isoform properties of medications (inductors and inhibitors) in both groups.

Methods

A cross-sectional, descriptive, comparative design was used. Baseline data from 98 BCS and 138 midlife women without cancer was analyzed from a behavioral intervention trial for menopausal symptoms.

Results

BCS were taking significantly more prescription medications and a larger variety of different types of medication classifications (p < 0.05) after controlling for group differences (race, noncancer comorbid conditions, marital status, income, and smoking) in demographics. Twenty-four women were taking at least one medication considered to be a cytochrome P450 isoforms (CYP) inhibitor or inducer capable of clinical drug–drug interactions with no differences in CYP inhibitors or inducers found between groups.

Conclusion

BCS are taking a vast array of medications during survivorship. It is unclear if prescription medications are managed by a single healthcare provider or several providers. Clinical implications are to monitor for possible interactions among the various prescription medications, over-the-counter medications, and supplements. Implications for behavioral and biomedical research are that clinical studies need to carefully assess and account for multiple medication uses.

Relevance of the study

The findings of this study are relevant to research and practice for both oncology and general practitioners. The importance of assessing medication information provides information about symptom management in individuals surviving cancer. In addition, the potential interaction of drugs impacts efficacy of various treatments and impacts compliance by patients.
Literatur
1.
Zurück zum Zitat Otte JL, Carpenter JS, Russell KM, Bigatti S, Champion VL (2010) Prevalence, severity, and correlates of sleep–wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 39(3):535–547PubMedCrossRef Otte JL, Carpenter JS, Russell KM, Bigatti S, Champion VL (2010) Prevalence, severity, and correlates of sleep–wake disturbances in long-term breast cancer survivors. J Pain Symptom Manage 39(3):535–547PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef
3.
Zurück zum Zitat Altman RB, Flockhart DA, Sherry ST, Oliver DE, Rubin DL, Klein TE (2003) Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13(1):3–5PubMedCrossRef Altman RB, Flockhart DA, Sherry ST, Oliver DE, Rubin DL, Klein TE (2003) Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13(1):3–5PubMedCrossRef
4.
Zurück zum Zitat Flockhart DA, Rae JM (2003) Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 3(1):3–5PubMedCrossRef Flockhart DA, Rae JM (2003) Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 3(1):3–5PubMedCrossRef
5.
Zurück zum Zitat Stearns V, Davidson NE, Flockhart DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4(3):143–153PubMedCrossRef Stearns V, Davidson NE, Flockhart DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4(3):143–153PubMedCrossRef
6.
Zurück zum Zitat Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRef Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478PubMedCrossRef
7.
Zurück zum Zitat Moore TA, Berger AM, Dizona P (2011) Sleep aid use during and following breast cancer adjuvant chemotherapy. Psychooncology 20(3):321–325PubMedCrossRef Moore TA, Berger AM, Dizona P (2011) Sleep aid use during and following breast cancer adjuvant chemotherapy. Psychooncology 20(3):321–325PubMedCrossRef
8.
Zurück zum Zitat Costantini C, Ale-Ali A, Helsten T (2011) Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med 14(5):563–566PubMedCrossRef Costantini C, Ale-Ali A, Helsten T (2011) Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med 14(5):563–566PubMedCrossRef
9.
Zurück zum Zitat Miller P, Demark-Wahnefried W, Snyder DC, Sloane R, Morey MC, Cohen H, Kranz S, Mitchell DC, Hartman TJ (2008) Dietary supplement use among elderly, long-term cancer survivors. J Cancer Surviv 2(3):138–148PubMedCrossRef Miller P, Demark-Wahnefried W, Snyder DC, Sloane R, Morey MC, Cohen H, Kranz S, Mitchell DC, Hartman TJ (2008) Dietary supplement use among elderly, long-term cancer survivors. J Cancer Surviv 2(3):138–148PubMedCrossRef
10.
Zurück zum Zitat Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, Mazurowska M, Anderson V, Wardell K, Cantwell MM (2011) Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat 128(2):473–482PubMedCrossRef Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, Mazurowska M, Anderson V, Wardell K, Cantwell MM (2011) Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat 128(2):473–482PubMedCrossRef
11.
Zurück zum Zitat Ridner SH, Dietrich MS (2008) Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum 35(1):57–63PubMedCrossRef Ridner SH, Dietrich MS (2008) Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum 35(1):57–63PubMedCrossRef
12.
Zurück zum Zitat Carpenter JS, Wu J, Burns DS, Yu M (2012) Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women. Cancer Nurs 35(3):195–202PubMedCrossRef Carpenter JS, Wu J, Burns DS, Yu M (2012) Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women. Cancer Nurs 35(3):195–202PubMedCrossRef
13.
Zurück zum Zitat Staff PDR (2011) PDR consumer guide to prescription drugs. PDR Consumer, New York, p 1828, 1 online resource Staff PDR (2011) PDR consumer guide to prescription drugs. PDR Consumer, New York, p 1828, 1 online resource
15.
Zurück zum Zitat Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol: Off J Am Soc Cli Oncol 26(4):665–673CrossRef Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol: Off J Am Soc Cli Oncol 26(4):665–673CrossRef
16.
Zurück zum Zitat Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol: Off J Am Soc Cli Oncol 30(9):936–942CrossRef Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol: Off J Am Soc Cli Oncol 30(9):936–942CrossRef
17.
Zurück zum Zitat North American Menopause Society N (2010) Menopause practice: a clinician’s guide, 4th edn. North American Menopause Society, Mayfield Heights North American Menopause Society N (2010) Menopause practice: a clinician’s guide, 4th edn. North American Menopause Society, Mayfield Heights
18.
Zurück zum Zitat Marchigiano G (1999) Calcium intake in midlife women: one step in preventing osteoporosis. Orthop Nurs/Natl Assoc Orthop Nurses 18(5):11–18, quiz 19–20 Marchigiano G (1999) Calcium intake in midlife women: one step in preventing osteoporosis. Orthop Nurs/Natl Assoc Orthop Nurses 18(5):11–18, quiz 19–20
19.
Zurück zum Zitat Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G (2011) The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 89(3):379–386PubMedCrossRef Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G (2011) The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 89(3):379–386PubMedCrossRef
Metadaten
Titel
Medication use in breast cancer survivors compared to midlife women
verfasst von
Julie L. Otte
Todd C. Skaar
Jingwei Wu
Menggang Yu
Kristin Ryker
Debra S. Burns
Janet S. Carpenter
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1727-5

Weitere Artikel der Ausgabe 7/2013

Supportive Care in Cancer 7/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.